Business
realised. We also implore the management in aca- demia not to treat the AHTSCF staff as second- class citizens, as is the case now, but to make the senior AHTSCF staff tenured or tenure-track fac- ulty. The AHTSCF staff’s salaries would then not come from the AHTSCF service revenue, but from the university’s operational budget itself. This is easily defendable because the Facilities and Administrative component of a funded grant, especially with a HTS component, hitherto has not been reflected in the AHTSCF revenue stream or budget. With the salaries covered, the AHTSCF can now offer its screening services at a somewhat reduced cost. This would enable the institutional investigators to easily afford AHTSCFs services which would in turn increase the number of incoming projects, the associated revenues, and thus make self-sustainability of AHTSCFs a reality rather than a dream.
Acknowledgements
The authors would like to thank Drs Joseph Heppert, Roy Jensen, Barbara Timmermann and Scott Weir for their continued support of the KU HTSL and drug discovery research at KU, and their dedication to the HTS laboratory’s continued mission of excellent service and self sustainability. KU-HTSL is a KU Cancer Center Shared Resource, and is funded in part by NIH Grant (P20 RR015563, Timmermann, PI) (COBRE Program of the NCRR).
DDW
Dr Peter McDonald holds a doctorate in molecular pharmacology from the University of Pittsburgh School of Medicine, Department of Pharmacology. Peter joined the University of Kansas High Throughput Screening laboratory in 2008. He pro- vides project consultation and screening services, including high throughput screening (HTS) and high content screening (HCS), and develops cost estimates for incoming projects.
Dr Anuradha Roy is interim director of the KU HTSL. Prior to joining KU, she led various aspects of drug discovery at PTC Therapeutics Inc after her postdoctoral work at Cleveland Clinic Foundation. She holds a doctorate in Biochemistry/Molecular Biology from Jawaharlal Nehru University (India). Anu leads enzyme- and cell-based screens at KU-HTSL.
Dr Rathnam Chaguturu was the previous director of KU-HTSL. He is currently the Senior Director- Exploratory Research, Center for Advanced Drug
Drug Discovery World Winter 2011/12 69
Research, SRI International in Harrisonburg, Virginia. Rathnam has more than 30 years of expe- rience in new lead discovery and development, exe- cuting high throughput screens and managing hit to lead projects. He has authored more than 50 research publications including reviews and book chapters, and holds 11 US patents. He is the founding president of the International Chemical Biology Society, and the Editor-in-Chief of the journal Combinatorial Chemistry and High Throughput Screening, published by Bentham. He is currently editing a book, tentatively titled, Collaborative Drug Discovery: Strategies for Academic, Industry and Government Partnerships, to be published later this year by Wiley & Sons.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80